Saturday, October 10, 2026
Saturday, October 10, 2026
Gerard F. Corbett
A corporate crisis does not always begin with a new event. Sometimes an old decision returns under circumstances that give it new meaning.
US-based skincare brand Neutrogena now faces that reality following the death of Hayden Panettiere, who represented the Kenvue-owned brand for approximately a decade. In her 2026 memoir and subsequent interviews, Panettiere alleged that the company ended their relationship after she spoke publicly about receiving treatment for postpartum depression. Her allegation received attention when the memoir appeared in May.
Following her death at age 36 on August 16, it has become the basis of calls for a boycott, widespread criticism and hostile comments across Neutrogena’s social-media accounts. As of August 19, the company had not publicly addressed either the allegation or her death, according to recent coverage. The Independent and the New York Post both reported receiving no response from the company.
That silence is no longer neutral. It allows an allegation about a decision made more than a decade ago to define the company today. Neutrogena may have information the public does not possess. Celebrity endorsement agreements are private, and the conclusion of a commercial relationship can involve many considerations. Panettiere gave her account. The company has not given its own. That distinction matters.
The company should not confirm facts it cannot verify, waive legitimate confidentiality obligations or publicly debate the life of a woman whose family is grieving. It should also not assume that contractual privacy relieves management of its responsibility to address a serious question about the company’s values.
The immediate issue is not whether Neutrogena can win an argument over the precise language of a 2015 contract. The issue is whether the company abandoned a longtime representative because she acknowledged receiving treatment for a medical condition experienced by mothers, and whether today’s management understands why that possibility has caused such anger.
Neutrogena must answer five questions.
Management should immediately review the company’s records, including the endorsement agreement, correspondence with Panettiere’s representatives and the internal discussions surrounding the relationship. Who recommended ending or not renewing the agreement? What reasons were documented? Was Panettiere’s disclosure of postpartum depression discussed? Was a morality clause invoked? Who approved the decision?
The company cannot respond credibly until it establishes the facts. This review should not become an open-ended investigation designed to postpone a public statement. The central events are specific. The relevant records should be identifiable.
If Neutrogena no longer possesses enough information to reach a conclusion, it should say so. An incomplete record is not a license to invent certainty.
Neutrogena should promptly acknowledge Panettiere’s death and express sympathy to her family, friends and colleagues. That statement must not become an advertisement for the brand or an attempt to appropriate her legacy. It should be human, brief and separate from the company’s defense. The company should then acknowledge the allegation directly:
Hayden Panettiere said that Neutrogena ended its relationship with her after she disclosed her treatment for postpartum depression. The company is reviewing the circumstances surrounding that decision and will address what it can responsibly establish.
This would not concede the allegation. It would demonstrate that management has heard it. The company should also state clearly that seeking treatment for postpartum depression is not a moral failure and would not, under its current policies, be considered one.
That should be an easy statement for management to make. If it is not, the company has identified a larger problem.
This response should not be left to a social-media manager confronting thousands of angry comments. The decision may have been made under previous ownership or management. That does not eliminate the responsibility of current leadership. Organizations inherit more than assets and brand recognition. They also inherit unresolved questions about past conduct. A senior executive should accept responsibility for establishing the facts and explaining the company’s position. The spokesperson does not need to accuse or defend predecessors. The spokesperson does need to show that present management understands the seriousness of the issue. A statement attributed only to “the Neutrogena team” will appear designed to disperse accountability. Someone must own the answer.
The company should not attack Panettiere’s credibility, release selective details about her personal difficulties or suggest that the public does not understand the complexities of celebrity contracts. Those approaches might strengthen a legal argument while destroying the company’s remaining credibility. It should not hide behind the statement that personnel or contractual matters are confidential. Confidentiality may limit detail. It does not prevent the company from explaining its principles.
It should not continue posting routine promotional content while ignoring the criticism. Scheduled messages about skincare products will appear indifferent when the company’s own channels have become the principal venue for demands for accountability. It should not use humor. Neutrogena recently answered criticism of another promotional campaign with a self-aware social-media response. This is not the same kind of controversy. A woman has died, her family is grieving and the dispute concerns mental health. Levity would be profoundly misplaced. Above all, the company should not issue a carefully worded tribute that praises Panettiere while avoiding what she said about her treatment by the brand. That would be perceived as an exercise in reputation management rather than respect.
If the review supports Panettiere’s account, Neutrogena should acknowledge that the company made the wrong decision and apologize without qualification. It should explain what has changed in its endorsement policies, its use of morality clauses and its treatment of mental-health disclosures. It should also determine whether similar decisions affected other representatives. If the records contradict or materially complicate her account, the company should explain the difference respectfully and provide as much substantiation as its obligations permit. Either conclusion must be followed by action.
Neutrogena could review every agreement containing a morality clause to ensure that seeking treatment for a mental-health condition cannot be treated as misconduct. It could establish a clear process for separating genuine reputational risk from the stigma surrounding illness. It could support credible work in maternal mental health, but only after addressing its own conduct.
A contribution or awareness campaign cannot purchase absolution. Corporate philanthropy has value when it reflects institutional change. When it replaces accountability, it looks transactional. This crisis presents a fundamental test for Neutrogena.
The company sells products associated with personal care. It built a long relationship with a young woman whose image helped represent the brand. She later alleged that the relationship ended when she publicly discussed seeking care for postpartum depression.
Management cannot erase that allegation with silence. It cannot wait for social-media attention to move elsewhere. It cannot respond only to the intensity of the boycott and ignore the reason people find the story credible.
The company must establish what happened, disclose what it responsibly can, acknowledge any failure and demonstrate what will change. The most important question is not whether Neutrogena can protect a contract written in 2015. It is whether the company can defend its values in 2026.
+++
Gerard F. Corbett is CEO, Redphlag.
You must be logged in to post a comment.
© 2026 Stratpair Ltd., trading as Strategic. Registered in Ireland: 747736
Neutrogena’s statement is welcome, but long overdue. Acknowledging that Hayden Panettiere felt unsupported is not the same as explaining the company’s decision or accepting responsibility for it. If Neutrogena wants the public to believe this is not who it is today, management must say what it learned, what has changed and how it will ensure that seeking help for a mental-health condition is never treated as a reputational liability. Regret matters. Accountability matters more.